Cargando…
Economic impact of a more extensive use of FENO testing on the Italian population with asthma
BACKGROUND: Asthma is a common chronic inflammatory airway affecting over 260 million people worldwide, and characterized, in the large majority of cases, by the so-called “type 2 inflammation”. Fractional exhaled nitric oxide (FE(NO)) testing is noninvasive point-of-care tool to assess type 2 infla...
Autores principales: | Rognoni, Carla, Milano, Carlo, Heffler, Enrico, Bonini, Matteo, Brussino, Luisa, Carpagnano, Giovanna Elisiana, Ricciardolo, Fabio Luigi Massimo, Costa, Francesco, Armeni, Patrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236694/ https://www.ncbi.nlm.nih.gov/pubmed/37268938 http://dx.doi.org/10.1186/s12931-023-02437-y |
Ejemplares similares
-
Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)
por: Heffler, Enrico, et al.
Publicado: (2020) -
Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2022) -
Biological therapy for severe asthma
por: Dragonieri, Silvano, et al.
Publicado: (2021) -
Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
por: Crimi, Claudia, et al.
Publicado: (2023) -
The Role of FeNO in Predicting Asthma
por: Pijnenburg, Mariëlle W.
Publicado: (2019)